CLL2-BIG - A Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed by Ibrutinib and GA101 Maintenance in Patients With Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 21
页数：3
相关论文
共 50 条
  • [41] Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG)
    Cramer, P.
    von Tresckow, J.
    Bahlo, J.
    Robrecht, S.
    Al-Sawaf, O.
    Langerbeins, P.
    Engelke, A.
    Fink, A. -M.
    Fischer, K.
    Tausch, E.
    Seiler, T.
    von Weikersthal, Fischer L.
    Hebart, H.
    Kreuzer, K. -A.
    Ritgen, M.
    Kneba, M.
    Wendtner, C. -M.
    Stilgenbauer, S.
    Eichhorst, B.
    Hallek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 24 - 24
  • [42] Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial
    Goede, Valentin
    Fischer, Kirsten
    Busch, Raymonde
    Engelke, Anja
    Eichhorst, Barbara
    Wendtner, Clemens M.
    Chagorova, Tatiana
    De la Serna, Javier
    Dilhuydy, Marie-Sarah
    Opat, Stephen
    Owen, Carolyn J.
    Samoylova, Olga
    Kreuzer, Karl-Anton
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Doehner, Hartmut
    Asikanius, Elina
    Humphrey, Kathryn
    Wenger, Michael K.
    Hallek, Michael
    BLOOD, 2013, 122 (21)
  • [43] Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Ferra, Christelle M.
    Rios Herranz, Eduardo
    Fernandez, Margarita
    Delgado, Julio
    Andreu, Rafael
    Angel Hernandez-Rivas, Jose
    Jose Terol, Maria
    Gonzalez, Marcos
    Baltasar Tello, Patricia
    de la Serna, Javier
    Ramirez Payer, Angel
    Ballester, Carmen
    Moreno, Carol
    Garcia-Marco, Jose A.
    Cordoba, Raul
    Yanez San Segundo, Lucrecia
    Casado Montero, Luis Felipe
    Bosch, Francesc
    BLOOD, 2019, 134
  • [44] A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20+ Malignant Disease
    Sehn, Laurie H.
    Assouline, Sarit E.
    Stewart, Douglas A.
    Mangel, Joy
    Pisa, Pavel
    Kothari, Jaimal
    Crump, Michael
    BLOOD, 2009, 114 (22) : 385 - 385
  • [45] Bendamustine, followed by obinutuzumab, acalabrutinib and venetoclax in patients (Pts) with relapsed/refractory chronic lymphocytic Leukemia (CLL): updated results of the CLL2-BAAG trial of the German CLL Study Group (GCLLSG)
    Cramer, Paula
    Fuerstenau, Moritz
    Robrecht, Sandra
    Giza, Adam
    Fink, Anna
    Fischer, Kirsten
    Langerbeins, Petra
    Al-Sawaf, Othman
    Tausch, Eugen
    Schneider, Christof
    Schetelig, Johannes
    Dreger, Peter
    Boettcher, Sebastian
    Kreuzer, Karl-Anton
    Schilhabel, Anke
    Brueggemann, Monika
    Kneba, Michael
    Wendtner, Clemens
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2023, 64 : S18 - S19
  • [46] Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial.
    Goede, Valentin
    Fischer, Kirsten
    Humphrey, Kathryn
    Asikanius, Elina
    Busch, Raymonde
    Engelke, Anja
    Wendtner, Clemens M.
    Samoylova, Olga
    Chagorova, Tatiana
    Dilhuydy, Marie-Sarah
    Torroba, Javier De La Serna
    Illmer, Thomas
    Opat, Stephen
    Owen, Carolyn
    Kreuzer, Karl A.
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Wenger, Michael
    Hallek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Phase II, multicenter trial, exploring 'chemosparing' strategy associating Obinutuzumab | Ibrutinib followed by an MRD driven strategy, in previously untreated symptomatic medically fit Chronic Lymphocytic Leukemia patients (CLL): preliminary results
    Michallat, Anne-Sophie
    Dilhuydy, Marie Sarah
    Rouille, Valerie
    Beatrice, Mahe
    Kamel, Laribi
    Bruno, Villemagne
    Salles, Gilles
    Tournilhac, Olivier
    Delmer, Alain
    Christelle, Portois
    Brigitte, Pegourie
    Leblond, Veronique
    Cecile, Tomowiak
    de Guibert, Sophie
    Orsini-Piocelle, Frederique
    Anne, Banos
    Philippe, Carassou
    Guillaume, Cartron
    Luc-Matthieu, Fornecker
    Loic, Ysebaert
    Dartigeas, Caroline
    Margot, Truchan
    Aurran-Schleinitz, Therese
    Cymbalista, Florence
    Lepretre, Stephane
    Levy, Vincent
    Magali, Le Garff Tavernier
    Carmen, Aanei
    Michel, Ticchioni
    Remi, Letestu
    Feugier, Pierre
    LEUKEMIA & LYMPHOMA, 2017, 58 : 129 - 130
  • [48] OBINUTUZUMAB (GA101) OR RITUXIMAB (R) plus CHLORAMBUCIL (CLB) VERSUS CLB ALONE IN PATIENTS WITH CLL AND PRE-EXISTING MEDICAL CONDITIONS (COMORBIDITIES): FINAL STAGE 1 RESULTS OF THE CLL11 PHASE 3 TRIAL
    Goede, V.
    Fischer, K.
    Humphrey, K.
    Asikanius, E.
    Busch, R.
    Engelke, A.
    Wendtner, C.
    Samoylova, O.
    Chagorova, T.
    Dilhuydy, M.
    De La Serna, J.
    Illmer, T.
    Opat, S.
    Owen, C.
    Kreuzer, K.
    Langerak, A.
    Ritgen, M.
    Stilgenbauer, S.
    Wenger, M.
    Hallek, M.
    HAEMATOLOGICA, 2013, 98 : 237 - 237
  • [49] Ibrutinib Lead-In Followed by Venetoclax in Patients With Chronic Lymphocytic Leukemia: Phase 2 CAPTIVATE Early Safety and Efficacy Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 6 - 6
  • [50] THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS
    Herter, S.
    Del Giudice, I.
    Schmidt, C.
    Fauti, T.
    Klein, C.
    Umana, P.
    Dyer, M. J. S.
    Foa, R.
    Grau, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 366 - 366
12345